Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy

Erica L. Fletcher, Joanna A. Phipps, Michelle M. Ward, Teresa Puthussery, Jennifer L. Wilkinson-Berka

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Diabetes is known to cause significant alterations in the retinal vasculature. Indeed, diabetic retinopathy is the leading cause of blindness in those of working age. Considerable evidence is emerging that indicates that retinal neurons are also altered during diabetes. Moreover, many types of neuronal deficits have been observed in animal models and patients prior to the onset of vascular compromise. Such clinical tools as the flash ERG, multifocal ERG, colour vision, contrast sensitivity and short-wavelength automated perimetry, all provide novel means whereby neuronal dysfunction can be detected at early stages of diabetes. The underlying mechanisms that lead to neuronal deficits are likely to be broad. Retinal glial cells play an essential role in maintaining the normal function of the retina. There is accumulating evidence that Müller cells are abnormal during diabetes. They are known to become gliotic, display altered potassium siphoning, glutamate and GABA uptake and are also known to express several modulators of angiogenesis. This review will examine the evidence that neurons and glia are altered during diabetes and the relationship these changes have with vascular compromise.

Original languageEnglish (US)
Pages (from-to)2699-2712
Number of pages14
JournalCurrent Pharmaceutical Design
Volume13
Issue number26
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Neuroglia
Blood Vessels
Angiogenesis Modulating Agents
Retinal Neurons
Color Vision
Visual Field Tests
Contrast Sensitivity
Blindness
gamma-Aminobutyric Acid
Retina
Glutamic Acid
Animal Models
Neurons

Keywords

  • Angiotensin
  • Diabetes
  • Muller cell
  • Pericyte
  • Photoreceptor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fletcher, E. L., Phipps, J. A., Ward, M. M., Puthussery, T., & Wilkinson-Berka, J. L. (2007). Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Current Pharmaceutical Design, 13(26), 2699-2712. https://doi.org/10.2174/138161207781662920

Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. / Fletcher, Erica L.; Phipps, Joanna A.; Ward, Michelle M.; Puthussery, Teresa; Wilkinson-Berka, Jennifer L.

In: Current Pharmaceutical Design, Vol. 13, No. 26, 09.2007, p. 2699-2712.

Research output: Contribution to journalArticle

Fletcher, EL, Phipps, JA, Ward, MM, Puthussery, T & Wilkinson-Berka, JL 2007, 'Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy', Current Pharmaceutical Design, vol. 13, no. 26, pp. 2699-2712. https://doi.org/10.2174/138161207781662920
Fletcher, Erica L. ; Phipps, Joanna A. ; Ward, Michelle M. ; Puthussery, Teresa ; Wilkinson-Berka, Jennifer L. / Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. In: Current Pharmaceutical Design. 2007 ; Vol. 13, No. 26. pp. 2699-2712.
@article{4cf1567eac8b4fd5a5d1d9e9b0718ece,
title = "Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy",
abstract = "Diabetes is known to cause significant alterations in the retinal vasculature. Indeed, diabetic retinopathy is the leading cause of blindness in those of working age. Considerable evidence is emerging that indicates that retinal neurons are also altered during diabetes. Moreover, many types of neuronal deficits have been observed in animal models and patients prior to the onset of vascular compromise. Such clinical tools as the flash ERG, multifocal ERG, colour vision, contrast sensitivity and short-wavelength automated perimetry, all provide novel means whereby neuronal dysfunction can be detected at early stages of diabetes. The underlying mechanisms that lead to neuronal deficits are likely to be broad. Retinal glial cells play an essential role in maintaining the normal function of the retina. There is accumulating evidence that M{\"u}ller cells are abnormal during diabetes. They are known to become gliotic, display altered potassium siphoning, glutamate and GABA uptake and are also known to express several modulators of angiogenesis. This review will examine the evidence that neurons and glia are altered during diabetes and the relationship these changes have with vascular compromise.",
keywords = "Angiotensin, Diabetes, Muller cell, Pericyte, Photoreceptor",
author = "Fletcher, {Erica L.} and Phipps, {Joanna A.} and Ward, {Michelle M.} and Teresa Puthussery and Wilkinson-Berka, {Jennifer L.}",
year = "2007",
month = "9",
doi = "10.2174/138161207781662920",
language = "English (US)",
volume = "13",
pages = "2699--2712",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "26",

}

TY - JOUR

T1 - Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy

AU - Fletcher, Erica L.

AU - Phipps, Joanna A.

AU - Ward, Michelle M.

AU - Puthussery, Teresa

AU - Wilkinson-Berka, Jennifer L.

PY - 2007/9

Y1 - 2007/9

N2 - Diabetes is known to cause significant alterations in the retinal vasculature. Indeed, diabetic retinopathy is the leading cause of blindness in those of working age. Considerable evidence is emerging that indicates that retinal neurons are also altered during diabetes. Moreover, many types of neuronal deficits have been observed in animal models and patients prior to the onset of vascular compromise. Such clinical tools as the flash ERG, multifocal ERG, colour vision, contrast sensitivity and short-wavelength automated perimetry, all provide novel means whereby neuronal dysfunction can be detected at early stages of diabetes. The underlying mechanisms that lead to neuronal deficits are likely to be broad. Retinal glial cells play an essential role in maintaining the normal function of the retina. There is accumulating evidence that Müller cells are abnormal during diabetes. They are known to become gliotic, display altered potassium siphoning, glutamate and GABA uptake and are also known to express several modulators of angiogenesis. This review will examine the evidence that neurons and glia are altered during diabetes and the relationship these changes have with vascular compromise.

AB - Diabetes is known to cause significant alterations in the retinal vasculature. Indeed, diabetic retinopathy is the leading cause of blindness in those of working age. Considerable evidence is emerging that indicates that retinal neurons are also altered during diabetes. Moreover, many types of neuronal deficits have been observed in animal models and patients prior to the onset of vascular compromise. Such clinical tools as the flash ERG, multifocal ERG, colour vision, contrast sensitivity and short-wavelength automated perimetry, all provide novel means whereby neuronal dysfunction can be detected at early stages of diabetes. The underlying mechanisms that lead to neuronal deficits are likely to be broad. Retinal glial cells play an essential role in maintaining the normal function of the retina. There is accumulating evidence that Müller cells are abnormal during diabetes. They are known to become gliotic, display altered potassium siphoning, glutamate and GABA uptake and are also known to express several modulators of angiogenesis. This review will examine the evidence that neurons and glia are altered during diabetes and the relationship these changes have with vascular compromise.

KW - Angiotensin

KW - Diabetes

KW - Muller cell

KW - Pericyte

KW - Photoreceptor

UR - http://www.scopus.com/inward/record.url?scp=34548763127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548763127&partnerID=8YFLogxK

U2 - 10.2174/138161207781662920

DO - 10.2174/138161207781662920

M3 - Article

VL - 13

SP - 2699

EP - 2712

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 26

ER -